Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Xin, McDermott, David F., Michaelson, M. Dror
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656499/
https://www.ncbi.nlm.nih.gov/pubmed/31036769
http://dx.doi.org/10.1634/theoncologist.2019-0165
_version_ 1783438644929888256
author Gao, Xin
McDermott, David F.
Michaelson, M. Dror
author_facet Gao, Xin
McDermott, David F.
Michaelson, M. Dror
author_sort Gao, Xin
collection PubMed
description Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors.
format Online
Article
Text
id pubmed-6656499
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-66564992019-07-29 Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma? Gao, Xin McDermott, David F. Michaelson, M. Dror Oncologist Commentaries Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell carcinoma (RCC). This commentary summarizes the clinical advances and reviews the potential implications for RCC and other advanced solid tumors. John Wiley & Sons, Inc. 2019-04-29 2019-06 /pmc/articles/PMC6656499/ /pubmed/31036769 http://dx.doi.org/10.1634/theoncologist.2019-0165 Text en © AlphaMed Press 2019
spellingShingle Commentaries
Gao, Xin
McDermott, David F.
Michaelson, M. Dror
Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
title Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
title_full Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
title_fullStr Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
title_full_unstemmed Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
title_short Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
title_sort enhancing antitumor immunity with antiangiogenic therapy: a clinical model in renal cell carcinoma?
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656499/
https://www.ncbi.nlm.nih.gov/pubmed/31036769
http://dx.doi.org/10.1634/theoncologist.2019-0165
work_keys_str_mv AT gaoxin enhancingantitumorimmunitywithantiangiogenictherapyaclinicalmodelinrenalcellcarcinoma
AT mcdermottdavidf enhancingantitumorimmunitywithantiangiogenictherapyaclinicalmodelinrenalcellcarcinoma
AT michaelsonmdror enhancingantitumorimmunitywithantiangiogenictherapyaclinicalmodelinrenalcellcarcinoma

Ejemplares similares